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A model-bAsed ApproAch for the evAluAtion of once dAily dosinG of lAmivudine in hiv-infected children (11) . The long half-life of lamivudine-triphosphate coupled with intracellular pooling of precursor lamivudine-diphosphate supported the investigation of once daily dosing in adults. In fact, a once daily dose regimen was subsequently approved for adults based on clinical studies which showed equivalent antiviral activity (12) and equivalent area-under-the-curve [AUC 0-24 ] of plasma lamivudine and intracellular lamivudine-triphosphate (13) following once versus twice daily dosing of the same total daily dose. Even though a formal concentration-antiviral effect relationship is lacking due to the difficulties in routinely measuring the intracellular lamivudine-triphosphate concentrations, the plasma AUC 0-24 of lamivudine can be considered the best plasma predictor of antiviral activity based on the mechanism of action and long half-life of the active moiety.
Currently lamivudine is labelled for twice daily administration in children based on clinical trials which demonstrated antiviral activity at doses yielding similar exposure to those observed in adults. Given the mechanism of action of lamivudine (14) the exposure-antiviral response to HIV infection is likely to be similar between children and adults. Therefore, a once daily dose regimen in children that can match the AUC 0-24 of the approved twice daily regimen in children or the once or twice daily regimen in adults should demonstrate equivalent antiviral activity in children. To that purpose, several studies have been conducted to explore the pharmacokinetics and feasibility of once daily dosing in children (15, 16) . Nevertheless, an integrated, model-based evaluation of the impact of developmental growth factors has not been performed for once daily dosing in children. It can be envisaged that the use of once daily dosing in children will allow alignment with the approval of once daily fixed-dose combination antiretroviral pills for the adult indication. The aim of this study is therefore to assess whether lamivudine pharmacokinetics after once daily dosing is comparable to lamivudine pharmacokinetics after twice daily administration to HIV-infected children between 3 months and 12 years old. The use of simulation scenarios is proposed as the basis for evidence synthesis on the suitability of this new regimen in children. Simulated pharmacokinetic profiles are characterised in a large hypothetic paediatric cohort to determine the dose rationale without the requirement for further enrolment of children into a clinical trial (17, 18) . Once daily dOsing Of lamivudine in Hiv-infected cHildren
methods
Simulations were performed to compare the systemic exposure of lamivudine after once daily dosing to historical values in children and adults and to explore how differences in demographic covariates affect steady-state exposure. The hypothetical population was represented by children between 3 months and 12 years old. For the purposes of our analysis, children were split into various age groups, each with 5 patients with different body weight (n=180). The correlation between age and body weight was based on the WHO weight-for-age tables (20) . Lamivudine total daily doses were determined according to the currently recommended dose and method of administration, as indicated in the latest Summary of Product Characteristics (21) .
A one-compartment model with first order absorption and elimination processes previously developed and validated by our group was used to simulate the pharmacokinetic profiles (Chapter 3). The model was built using pharmacokinetic data in 77 HIV-infected children receiving lamivudine both as twice and once daily dosing regimens. Body weight was found to be exponentially correlated to clearance and volume of distribution. Given that formulation was not found to influence the pharmacokinetic parameters, the same model was used to predict lamivudine pharmacokinetics in children receiving tablets or solution.
The frequency and times for pharmacokinetic sampling were based on a serial sampling scheme to mimic current practice with regard to estimating AUC over the dosing interval.
Concentration vs. time data was then integrated using the trapezoidal rule to ensure realistic estimates of variability, as observed in a typical non-compartmental analysis. The hypothetical experimental protocol is depicted in figure 1 . Given that a significant concentration-effect relationship for lamivudine could not be found in the past, the adequacy of the simulated dosing regimens was assessed graphically by determining the fraction of the paediatric population reaching systemic exposure comparable to AUC 0-24 values previously observed in studies of adults on approved once and twice daily regimens and children on approved twice daily regimens.
Cmax values of the paediatric population were also compared to historical values of Cmax from previous clinical trials. Simulations were performed using NONMEM version 6.2. Results were graphically summarised using R 2.8.2. 
results
Simulations were performed using a population pharmacokinetic model previously developed and validated by our group. The goodness of fit and visual predictive checks are shown in figure 2.
Figure 2 (a) Goodness-of-fit. Left upper panel shows population prediction (PRED) vs. observed concentration values (DV). Right upper panel shows individual predictions (IPRE) vs. observed concentration values (DV). Left lower panel shows conditional weighted residuals (CWRES) vs. population predictions (PRED). Right lower panel shows conditional weighted residuals (CWRES) vs. time (TIME). (b) Visual predictive check (VPC) of the population pharmacokinetic model for lamivudine.
Based on the original parameter estimates, the distribution of the area under the curve (AUC 0-
24
) and peak concentration (Cmax) values associated with a once daily dosing regimen for lamivudine were evaluated in a hypothetical group of paediatric patients. In total, the simulated population consisted of 180 patients between 3 months and 12 years old, which represent a population with comparable demographic characteristics of HIV-infected children in a typical clinical setting. The demographic characteristics of the simulated population is summarised in Table 1. In   table 2 the doses of lamivudine administered to the simulated population are depicted.
Once daily dOsing Of lamivudine in Hiv-infected cHildren The simulation results are presented graphically in figures 
discussions And conclusions Evidence synthesis by modelling and simulation
Undoubtedly, the use of once daily dosing of antiretroviral drugs in HIV-infected children may offer significant clinical advantages, especially in resource limited countries. There can be several benefits for both children and caregivers and adherence may be strongly maximised, with consequent improvements in treatment outcome.
Given that previous studies have shown similar pharmacokinetics between once and twice daily dosing and evidence on the preference of caregivers for once daily regimen, evidence synthesis rather than new evidence generation needs to be considered to support once daily dosing of lamivudine in HIV-infected children. We have used a model-based approach to evaluate whether differences exist in the pharmacokinetics of lamivudine after once daily dosing, as comparable to the achieved exposure after twice daily administration. Our results clearly show that simulation scenarios offer the possibility to evaluate the potential implications of changes in dosing regimen based on existing evidence in the adult population and limited experience in children.
It is unfortunate that historically population pharmacokinetic models have been used pri- 
Once daily dosing regimen: systemic exposure
Simulation scenarios show that lamivudine AUC 0-24 reached after once daily dosing are comparable to historical values in children on a twice daily regimen of lamivudine and adults receiving the approved once or twice daily lamivudine regimens. Figure 3 shows that the youngest group of children (between 0 and 14 kg) had quite a lower exposure compared to the older, heavier children. This fact, previously shown by Burger et al (24), could be partly explained by a slightly lower dose that the small children receive (as shown in table 3). Effectively, higher mg/kg doses are administered with the score tablet dosage regimens due to the pre-defined tablets strengths (either 75mg half tablet or 150mg whole tablet) and because of the weight band cutoffs selected to minimise under-dosing in heavier children. Therefore, lighter children in the same weight band receive doses that are substantially higher than the 8mg/kg/day when the solution is administered. There may also be some effect of the formulation, since these children receive solution and the heavy ones receive tablets, as shown in a recent study from Kasirye et
al. (25)
Once daily dOsing Of lamivudine in Hiv-infected cHildren Once daily dosing regimen: peak concentrations
As anticipated from drugs showing linear pharmacokinetics, the reduction in dosing frequency resulted in an increase in median Cmax by approximately two-fold. Figure 4 shows that the maximum peak concentration reached after once daily dosing is much higher compared to twice daily administration. Once daily administration of lamivudine to HIV-infected children also results in higher Cmax than the historical values observed in adults and children during previous clinical trials in which twice daily dosing has been used. Given that once daily lamivudine was approved for use in adults based on good safety and efficacy and the positive tolerability and safety profile of once daily lamivudine was observed in small studies of children (28), the predicted increase in Cmax after once daily administration is unlikely to result in a higher risk of adverse events. Again Cmax values appear to be slightly lower for children lighter than 14 kg. However the simulated maximum peak concentration in this group of children is comparable with reference Cmax values in adults receiving once daily dosing and higher than reference Cmax values in children receiving lamivudine twice daily and in adults receiving lamivudine twice daily.
Clearly one of the major concerns about once daily administration of antiretroviral drugs is the higher risk of viral failure. In adults it has been shown that once daily lamivudine in combination with zidovudine and efavirenz would provide comparable treatment outcome as twice daily lamivudine (12) . It has also been shown that didanosine, another NRTI with similar pharmacokinetic properties as lamivudine, allows for once daily administration without increased risk of viral failure (29-31). Regarding the increased risk of drug resistance, previous studies demonstrated that once daily dosing of antiretrovirals is strongly correlated to increased patient adherence to therapy. Given that high levels of adherence may avoid development of resistance, the use of once daily dosing regimen is not expected to increase the probability of virus mutations and drug resistance.
limitations
One of the main limitations in our study was that lamivudine plasma pharmacokinetics can only be considered as a limited marker of drug exposure as it is the intracellular lamivudine triphosphate metabolite that becomes pharmacologically active. However, no alternative is available due to the requirements for adequate sampling of intracellular concentrations of nucleoside transcriptase inhibitor triphosphate, which is logistically and technically difficult. This is further complicated by the volume of blood required for the bioanalysis of intracellular lamivudine triphosphate concentrations, which makes serial evaluations impractical for paediatric patients.
Instead, we have made explicit assumptions about the use of plasma concentrations, namely that equilibrium between plasma and intracellular concentrations is rapidly reached and drug distribution into cells is driven by a first order process, without the risk of saturation occurring within the range of concentrations observed after once or twice daily dosing.
conclusions
In conclusion, the possibility of evaluating the implication of different dosing regimens using a model-based approach shows one of the various applications of virtual clinical trials in paediatric clinical pharmacology research. Our findings strongly suggest that when the same total daily lamivudine dose is administered, the reduction in dosing frequency to once daily does not represent a potential risk of under-or over-dosing in the paediatric population. Taking into account the evidence regarding acceptability and adherence in previous paediatric and adult HIV trials, the current results provides evidence for an alternative, once daily dosing regimen, with the advantages of improved adherence and consequently efficacy and clinical outcome for children, particularly in resource limited settings.
